Clinical trial · people
Pancragen lowered blood sugar and insulin in older type 2 diabetes
Checked against the paper Clinical trialPublished by PepVault
The takeaway
This is an early, small human study in which pancragen lowered blood sugar and insulin measures in older people with type 2 diabetes, but it is not strong proof on its own.
- Kind
- Clinical trial
- Studied in
- People
- Published
- 2011
- Journal
- Bull Exp Biol Med
What they tested
The team set out to test whether the tetrapeptide pancragen could improve blood sugar control and insulin resistance in older people with type 2 diabetes.
How the study was done
A small clinical study in older adults: 30 healthy people and 33 patients with type 2 diabetes. Some of the patients with diabetes were given pancragen and were compared with patients who did not receive it.

What they found
At night, the patients with type 2 diabetes made 70% less melatonin, a sleep-linked hormone, than healthy people of the same age. In the patients given pancragen, fasting blood sugar fell, and so did blood sugar during a standard glucose tolerance test (a drink-and-measure sugar test). Their plasma insulin and their insulin resistance index (a measure of how poorly the body responds to insulin) also went down. Patients who did not get pancragen showed no change in these blood sugar measures.
What it doesn’t show
This was a small study in older adults that compared patients given pancragen with patients who got none. It does not show how long the effects last or how pancragen compares with standard diabetes care.
The paper
Korkushko et al. Prospects of using pancragen for correction of metabolic disorders in elderly people. Bull Exp Biol Med. 2011.
The compound
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.